Neutralizing antibodies to bovine herpesviruses types 1 (BHV-1) and 5 (BHV-5) induced by an experimental, oil-adjuvanted, BHV-1 vaccine

Petzhold, Sylio Alfredo; Reckziegel, Paulo Estanisláo; Prado, J. A. P.; Teixeira, João Carlos Freitas; Wald, Vera Beatriz; Esteves, Paulo Augusto; Spilki, Fernando Rosado; Roehe, Paulo Michel

doi:10.1590/s1413-95962001000400007

Cited by 10 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, as may be expected, the levels of cross-reactivity were higher when serum samples were tested against BoHV-5 isolates than against BoHV-1 isolates. The serological cross-reactivity between BoHV-1 and BoHV-5 has also been demonstrated in other vaccine studies (Petzhold et al 2001, Vogel et al 2002, Silva et al 2007a.…”

Section: Discussionsupporting

confidence: 57%

Immunogenicity of an inactivated bovine herpesvirus type 5 strain defective in thymidine kinase and glycoprotein E

et al. 2010

View full text Add to dashboard Cite

RESUMO.-[Imunogenicidade de uma cepa inativada do herpesvírus bovino tipo 5 defectiva na timidina quinase e glicoproteína E.] A imunogenicidade de vacina experimental inativada, produzida com uma cepa do herpesvírus bovino tipo 5 defectiva nos genes da timidina quinase e glicoproteína E (BoHV-5 gE/TKΔ) foi avaliada em bovinos e o resultado foi comparado com a resposta induzida pela cepa parental do The immunogenicity of an inactivated, experimental vaccine based on a bovine herpesvirus type 5 strain defective in thymidine kinase and glycoprotein E (BoHV-5 gE/ TKΔ) was evaluated in cattle and the results were compared with a vaccine containing the parental BoHV-5 strain (SV507/99). To formulate the vaccines, each virus (wildtype SV507/99 and BoHV-5 gE/TKΔ) was multiplied in cell culture and inactivated with binary ethyleneimine (BEI). Each vaccine dose contained approximately of 10 7.5 TCID 50 of inactivated virus mixed with an oil-based adjuvant (46:54). Forty calves, 6 to 9-monthsold, were allocated into two groups of 20 animals each and vaccinated twice (days 0 and 22pv) by the subcutaneous route with either vaccine. Serum samples collected at day 0 and at different intervals after vaccination were tested for virus neutralizing (VN) antibodies against the parental virus and against heterologous BoHV-5 and BoHV-1 isolates. The VN assays demonstrated seroconversion to the respective homologous viruses in all vaccinated animals after the second vaccine dose (mean titers of 17.5 for the wildtype vaccine; 24.1 for the recombinant virus). All animals remained reagents up to day 116 pv, yet showing a gradual reduction in VN titers. Animals from both vaccine groups reacted in similar VN titers to different BoHV-1 and BoHV-5 isolates, yet the magnitude of serological response of both groups was higher against BoHV-5 field isolates. Calves vaccinated with the recombinant virus did not develop antibodies to gE as verified by negative results in a gE-specific ELISA, what would allow serological differentiation from naturally infected animals. Taken together, these results indicate that inactivated antigens of BoHV-5 gE/TK recombinant virus induced an adequate serological response against BoHV-5 and BoHV-1 and thus can be used as an alternative, differential vaccine candidate. inativados emulsionado em adjuvante oleoso (46:54). Quarenta bezerros de raças cruzadas, com idade entre seis a nove meses, foram alocados em dois grupos de 20 animais cada e vacinados duas vezes (dia 0 e 22 pv) pela via subcutânea com uma das vacinas. Amostras de soro foram coletadas no dia 0 e a vários intervalos após vacinação para a pesquisa de anticorpos neutralizantes frente ao vírus homólogo ou frente a isolados de BoHV-5 e BoHV-1. Os testes de soroneutralização (SN) demonstraram que todos os animais soroconverteram após a segunda dose da vacina (títulos médios de 17,5 para o grupo SV507/99; 24,1 para o grupo BoHV-5 gE/TKΔ). Todos os animais mantiveram níveis de anticorpos neutralizantes até o dia 116 pv, no entanto foi observada uma redução ...

show abstract

Section: Discussionsupporting

confidence: 57%

Immunogenicity of an inactivated bovine herpesvirus type 5 strain defective in thymidine kinase and glycoprotein E

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The viral suspension was inactivated with binary ethylenimine (BEI) as described previously (Bahnemann et al 1974). The vaccine was prepared as a water-in-oil type emulsion and subjected to usual controls, as recommended (Petzhold et al 2001) and the suspension was stored at 4°C until use. The inactivation process was evaluated by titration of the inactivated suspension in a 96 wells plate, followed by the inoculation of serial tenfold dilutions of the suspension in 25cm 2 cell culture flasks, according to usual methods.…”

Section: Vaccine Productionmentioning

confidence: 99%

Efficacy of a gE-deleted, bovine herpesvirus 1 (BoHV-1) inactivated vaccine

Silva

Esteves²,

Dezen

et al. 2009

Pesq. Vet. Bras.

View full text Add to dashboard Cite

Pesq. Vet. Bras. 29(7): 545-551, julho 2009 RESUMO.-[Eficácia de uma vacina inativada, gE-deletada, contra o herpesvírus bovino tipo 1 (BoHV-1).] O Herpesvírus bovino tipo 1 (BoHV-1) é reconhecido como um importante agente de perdas econômicas em bovinos. Vacinação tem sido amplamente empregada para minimizar as perdas conseqüentes a infecções com o BoHV-1. Reportamos previamente o desenvolvimento de uma vacina diferencial para BoHV-1, baseada em um recombinante do qual a glicoproteína gE (gE) foi deletada (265gE -). No presente trabalho foi realizada a avaliação da eficácia de tal recombinante como vacina inativada. Cinco bovinos soronegativos para BoHV-1 foram vacinadas por via intramuscular no dia 0 e revacinadas 30 dias Bovine herpesvirus type 1 (BoHV-1) is recognized as a major cause of economic losses in cattle. Vaccination has been widely applied to minimize losses induced by BoHV-1 infections. We have previously reported the development of a differential BoHV-1 vaccine, based on a recombinant glycoprotein E (gE)-deleted virus (265gE -). In present paper the efficacy of such recombinant was evaluated as an inactivated vaccine. Five BoHV-1 seronegative calves were vaccinated intramuscularly on day 0 and boostered 30 days later with an inactivated, oil adjuvanted vaccine containing an antigenic mass equivalent to 10 7.0 fifty per cent cell culture infectious doses (CCID 50 ) of 265gE -. Three calves were kept as non vaccinated controls. On day 60 post vaccination both vaccinated and controls were challenged with the virulent parental strain. No clinical signs or adverse effects were seen after or during vaccination. After challenge, 2/5 vaccinated calves showed mild clinical signs of infection, whereas all non vaccinated controls displayed intense rhinotracheitis and shed virus for longer and to higher titres than vaccinated calves. Serological responses were detected in all vaccinated animals after the second dose of vaccine, but not on control calves. Following corticosteroid administration in attempting to induce reactivation of the latent infection, no clinical signs were observed in vaccinated calves, whereas non vaccinated controls showed clinical signs of respiratory disease. In view of its immunogenicity and protective effect upon challenge with a virulent BoHV-1, the oil adjuvanted preparation with the inactivated 265gE -recombinant was shown to be suitable for use as a vaccine.INDEX TERMS: Bovine herpesvirus type 1, BoHV-1, recombinant vaccine, inactivated vaccine.Pesq. Vet. Bras. 29 (7)

show abstract

“…A extensiva reatividade sorológica cruzada entre esses vírus sugere que animais adequadamente imunizados contra o BoHV-1 poderiam também estar protegidos contra o BoHV-5 (FLORES, E.F. comunicação pessoal). Portanto, embora ainda não existam vacinas comerciais para o BoHV-5, o uso de vacinas contra o BoHV-1 é sugerido como tentativa de reduzir a circulação do vírus, bem como as perdas associadas com a infecção pelo mesmo (PETZHOLD et al, 2001).…”

Section: Immunogenicity Of Commercial Inactivated Bovine Herpesvirus unclassified

Imunogenicidade de vacinas comerciais inativadas contra o herpesvírus bovino tipo 1

2007

View full text Add to dashboard Cite

O presente trabalho avaliou a imunogenicidade de seis vacinas comerciais contendo antígenos inativados do herpesvírus bovino tipo 1 (BoHV-1): uma brasileira (BR), uma norte-americana (US), duas uruguaias (UR1 e UR2) e duas argentinas (ARG1 e ARG2). Para isso, grupos de bovinos foram vacinados com duas doses (dias 0 e 21) de cada uma das vacinas. Anticorpos neutralizantes contra o BoHV-1 e o BoHV-5 foram pesquisados no soro colhido 21 dias após a segunda dose. Com exceção das vacinas US e UR1, as demais vacinas induziram títulos baixos de anticorpos na maioria dos animais. Os títulos induzidos pela vacina US (média geométrica, GMT=38) foram superiores aos demais (P<0,05). A vacina UR1 induziu títulos (GMT=20,2) superiores aos induzidos pelas vacinas BR (GMT=8,7), UR2 (GMT=7,3), ARG1 (GMT=10) e ARG2 (GMT=6,3) (P<0,05), que não diferiram entre si (P>0,05). A vacina US induziu títulos superiores a 16, referência mínima para se relacionar com proteção, em 7 animais (87,5%). As demais vacinas induziram títulos inferiores a 16 em 62,5% (5 de 8, BR), 33,3% (4 de 9, UR1), 75% (6 de 8, UR2) e 83,3% dos bezerros (5 de 6, ARG2). A vacina ARG1 apresentou performance ainda inferior, apenas três animais (37,5%) soroconverteram, ainda assim em títulos baixos. Os títulos neutralizantes contra o BoHV-5, um vírus antigenicamente relacionado ao BoHV-1, foram inferiores aos anti-BoHV-1 em todos os grupos vacinais; porém, para os grupos BR, ARG1 e ARG2, as diferenças não foram significativas (P>0,05). Os títulos baixos de anticorpos induzidos pela maioria das vacinas, mesmo quando testadas a um intervalo ideal para a produção de resposta sorológica, indicam a necessidade de se reavaliarem os critérios para o licenciamento e/ou importação de vacinas contra o BoHV-1 no país.

show abstract

Neutralizing antibodies to bovine herpesviruses types 1 (BHV-1) and 5 (BHV-5) induced by an experimental, oil-adjuvanted, BHV-1 vaccine

Cited by 10 publications

References 0 publications

Immunogenicity of an inactivated bovine herpesvirus type 5 strain defective in thymidine kinase and glycoprotein E

Immunogenicity of an inactivated bovine herpesvirus type 5 strain defective in thymidine kinase and glycoprotein E

Efficacy of a gE-deleted, bovine herpesvirus 1 (BoHV-1) inactivated vaccine

Imunogenicidade de vacinas comerciais inativadas contra o herpesvírus bovino tipo 1

Contact Info

Product

Resources

About